首页> 外文OA文献 >CN2 A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations

【2h】

CN2 A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations

机译：CN2用于一线治疗转移性非小细胞肺癌（Nsclc）Egfr外显子19缺失或外显子21（L858r）取代突变的患者的比较成本效用分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Carlson J.J.; Slejko J.F.; Goertz H.; Veenstra D.L.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. U.S. Foodand drug administrationapproval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations [J] . KhozinS., BlumenthalG.M., JiangX., The oncologist . 2014,第7期

机译：美国食品和药物管理局批准摘要：厄洛替尼用于表皮生长因子受体外显子19缺失或外显子21（L858R）替代突变的转移性非小细胞肺癌的一线治疗
2. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations [J] . Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang, The oncologist . 2014,第7期

机译：美国食品和药物管理局批准摘要：厄洛替尼用于表皮生长因子受体外显子19缺失或外显子21（L858R）替代突变的转移性非小细胞肺癌的一线治疗。
3. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea [J] . Baek Jin Ho, Sun Jong-Mu, Min Young Joo, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2015,第2期

机译：EGFR酪氨酸激酶抑制剂对EGFR突变的非小细胞肺癌患者的疗效，第19外显子缺失和第21外显子L858R除外：韩国的一项回顾性分析
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Design, Construction, and Verification of a LATE-PCR and Lights-On/Lights-Off Probe Assay for Mutation Detection in Exons 18-21 of the EGFR Gene: Implications for Molecular Diagnosis of Non-Small Cell Lung Carcinoma [D] . Tetrault, Shana Augustin 2012

机译：用于EGFR基因外显子18-21突变检测的LATE-PCR和开/关灯探针检测的设计，构建和验证：对非小细胞肺癌的分子诊断意义
6. U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations [O] . Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang, 2014

机译：美国食品药物管理局批准摘要：厄洛替尼用于表皮生长因子受体外显子19缺失或外显子21（L858R）替代突变的转移性非小细胞肺癌的一线治疗。
7. Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan [O] . Jonathan Graham, Stephanie Earnshaw, Kate Burslem, 2018

机译：AFATINIB对一线转移性非小细胞肺癌患者的预算冲击分析，表皮生长因子受体外显子19缺失或外显子21替代突变在美国卫生计划中

CN2 A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations

著录项

引文网络

相似文献

相关主题

期刊订阅